Evaluation of the protection against myxomatosis and viral haemorrhagic disease of rabbit conferred by a bivalent vaccine administered intradermally

De FOUCAULD J., FOURNIER D.

A group of rabbits was vaccinated intradermally at 4 weeks of age with a homologous SG33 strain myxomatosis vaccine and at 10 weeks of age with a bivalent vaccine containing the ""myxomatosis"" (SG33 strain) attenuated component and the ""rabbit haemorrhagic disease"" (VHD) component. Some of the vaccinated rabbits, along with unvaccinated control rabbits, were challenged with a virulent myxomatosis virus, approximately 4 months after vaccination with the bivalent vaccine. All the control rabbits developped myxomatosis within 4 days. None of the vaccinated animals were affected with the disease. One year after vaccination with the bivalent vaccine, all the remaining vaccinated rabbits along with control rabbits, were challenged with a virulent VHD virus. Eight out often control rabbits and one out oftwelve vaccinated animais died. As a result of these preliminary trials we can envisage a vaccination schedule for breeding animals which includes a bivalent vaccine against viral haemorrhagic disease of rabbits and myxomatosis, being given intradermally.

LET'S STAY CONNECTED